Sector: health
Conviction from: NASDAQS&P
52-week range: 112.65309.35
Develops, manufactures and markets DNA sequencing and array-based systems, consumables and software used in genomic research and clinical diagnostics.
5 tracked filer(s) hold this · 1 opened, 1 added, 3 trimmed in 30-SEP-2026
Aggregate 13FScore 60 — mean of 5 scored holder(s) · buyers (new/add) avg 52. Higher = the smart money in this name has the better track record.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|
| Paul Tudor Jones / Tudor | 61 | New buy | 3,600 | $985,248 | 0.0% |
| Ancora | 42 | Added +108% | 100 | $27,368 | 0.0% |
| Keith Meister / Corvex | 69 | Trimmed -73% | 770,350 | $210,829,388 | 6.4% |
| Steve Cohen / Point72 | 75 | Trimmed -30% | 67,300 | $18,418,664 | 0.0% |
| Bridgewater | 55 | Trimmed -94% | 773 | $211,555 | 0.0% |
Beyond 13F — activists, insiders, politicians & research
2 disclosed trade(s) by 1 filer(s).
2 disclosed trade(s) by 1 filer(s).
| Report | Date | Stance |
|---|
| #135 — State of the Themes: The End of the Trade (As We Know It) | 2026-11-04 | WATCH |
| #134 — Citrini Therapeutics: We Wanted to Use Claude to Create a New Drug | 2026-10-20 | WATCH |